P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)

• V. Gupta,
• A. Yacoub,
• S. Verstovsek,
• R. A. Mesa,
• C. N. Harrison,
• G. Barosi,
• J.-J. Kiladjian,
• H. J. Deeg,
• S. Fazal,
• L. Foltz,
• R. J. Mattison,
• C. B. Miller,
• V. Parameswaran,
• C. Hernandez,
• J. Zhang,
• M. Talpaz

Affiliations

V. Gupta

1 Princess Margaret Cancer Centre, Toronto, Canada

A. Yacoub

2 University of Kansas Medical Center, Kansas City

S. Verstovsek

3 The University of Texas MD Anderson Cancer Center, Houston

R. A. Mesa

4 Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, United States of America

C. N. Harrison

5 Guy’s and St Thomas’ Hospital, London, United Kingdom

G. Barosi

6 Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

J.-J. Kiladjian

7 Hôpital Saint-Louis, Université de Paris, INSERM, Paris, France

H. J. Deeg

8 Fred Hutchinson Cancer Center, Seattle

S. Fazal

9 Allegheny Health Network Cancer Institute, Pittsburgh, United States of America

L. Foltz

10 St. Paul’s Hospital, University of British Columbia, Vancouver, Canada

R. J. Mattison

11 University of Wisconsin Carbone Comprehensive Cancer Center, Madison

C. B. Miller

12 Ascension Saint Agnes Hospital, Baltimore

V. Parameswaran

13 Avera Cancer Institute, Sioux Falls

C. Hernandez

14 Bristol Myers Squibb, Princeton

J. Zhang

14 Bristol Myers Squibb, Princeton

M. Talpaz

15 University of Michigan Comprehensive Cancer Center, Ann Arbor, United States of America